retatrutide type 2 diabetes phase 2 trial results

retatrutide type 2 diabetes phase 2 trial results meets primary endpoints in two III obesity trials, reporting up to 22.6% weight loss – touchENDOCRINOLOGY A Study of Retatrutide (LY3437943)

Name: retatrutide type 2 diabetes phase 2 trial results meets primary endpoints in two III obesity trials, reporting up to 22.6% weight loss – touchENDOCRINOLOGY A Study of Retatrutide (LY3437943)
Brand: www.cmvroncone.com
SKU: 71360703350
Price: 25.72 USD
Availability: InStock
Rating: 4.0261 (5 reviews)

SKU: 71360703350

4.0

USD25.72 USD68.72

Pay in 4 interest-free payments of $6.43 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 21 - Aug 26

Description

Doctors must look at these to figure out the best treatment

In contrast, self-pay obesity patients will prioritise the higher efficacy of injectables over the convenience of oral pills

Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes